echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hisun Pharmaceutical Tofacitib Citrate Tablets Obtained Drug Registration Certificate

    Hisun Pharmaceutical Tofacitib Citrate Tablets Obtained Drug Registration Certificate

    • Last Update: 2021-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 19, Hisun Pharmaceutical issued an announcement stating that the company had recently received tofacitib citrate tablets to obtain a drug registration certificate.


    Tofacitinib citrate tablets are suitable for moderate to severely active rheumatoid arthritis (RA) adult patients with insufficient or intolerable methotrexate efficacy, and can be improved with methotrexate or other non-biological improvements Disease antirheumatic drugs (DMARD) are used in combination.


    Tofacitinib citrate was developed by Pfizer and was approved by the US FDA on November 6, 2012, under the trade name XELJANZ®.


    On January 15, 2019, the State Food and Drug Administration accepted the company's application for drug registration of tofacitib citrate tablets.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.